Supplementary Tables S1-S15 from Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma

Supplemental Table S1. Genome-wide RNAi toxicity screen z-scores, related to Supplemental Figure S1, Supplemental Table S2. Percent DNA copy number gain in melanoma tumor samples compared to normal skin, related to Supplemental Figure S1, Supplemental Table S3. Melanoma panel siRNA toxicity, related to Supplemental Figure S1, Supplemental Table S4. Whole genome transcript profiles, related to Supplemental Figure S1, Supplemental Table S5. GISTIC analysis and expression correlation of candidate melanoma hits, related to Supplemental Figure S1, Supplemental Table S6. SOX10 ChIPSeq, related to Supplemental Figure S3, Supplemental Table S7. SOX10 ChIPSeq motif targets, related to Supplemental Figure S3, Supplemental Table S8. SOX10 ChIPSeq motif targets hypergeometric distribution analysis, related to Supplemental Figure S3, Supplemental Table S9. Whole genome transcript arrays with siRNAs, related to Supplemental Figure S3, Supplemental Table S10. Candidate SOX10 targets, related to Supplemental Figure S3, Supplemental Table S11. Expression correlations in patient samples, related to Supplemental Figure S3, Supplemental Table S12. Elastic net prediction scores, related to Figures 1, 2 and 3, Supplemental Figures S4, S5 and S7, Supplemental Table S13. Elastic net prediction scores, related to Figure 2, Supplemental Table S14. S2N analysis of gene transcripts between TBK1i-sensitive and -resistant BRAF wild-type melanoma cell lines, related to Figure 3, Supplemental Table S15. TMT-phosphoproteomics peptide quantification, related to Figure S12.